Vantictumab manufacturers
- Vantictumab
-
- $247.00
-
2026-08-20
- CAS:1345009-45-1
- Purity: 99% (SDS-PAGE); 97.7% (SEC-HPLC)
- Supply Ability: 10g
|
| | Vantictumab Basic information |
| Product Name: | Vantictumab | | Synonyms: | Vantictumab;Research Grade Vantictumab (DHJ82501);Vantictumab (anti-FZD);Research Grade Vantictumab | | CAS: | 1345009-45-1 | | MF: | | | MW: | 0 | | EINECS: | | | Product Categories: | | | Mol File: | Mol File | ![Vantictumab Structure]() |
| | Vantictumab Chemical Properties |
| form | Liquid | | color | Colorless to light yellow |
| | Vantictumab Usage And Synthesis |
| Uses | Vantictumab (OMP-18R5) is a fully human IgG2 monoclonal antibody. Vantictumab inhibits Wnt pathway signaling by binding to FZD1/2/5/7/8 receptors. Vantictumab can be studied against cancers through direct actions on tumor cells, including CSCs, and effects on the stroma, such as metastatic HER2-negative breast cancer and metastatic pancreatic adenocarcinoma[1][2][3]. | | References | [1] Davis SL, et al. A phase 1b dose escalation study of Wnt pathway inhibitor vantictumab in combination with nab-paclitaxel and gemcitabine in patients with previously untreated metastatic pancreatic cancer. Invest New Drugs. 2020 Jun;38(3):821-830. DOI:10.1007/s10637-019-00824-1
[2] Diamond JR, et al. Phase Ib clinical trial of the anti-frizzled antibody vantictumab (OMP-18R5) plus paclitaxel in patients with locally advanced or metastatic HER2-negative breast cancer. Breast Cancer Res Treat. 2020 Nov;184(1):53-62. DOI:10.1007/s10549-020-05817-w
[3] Smith D C, et al. Abstract B24: Biomarker analysis in the first-in-human phase 1a study for vantictumab (OMP-18R5; anti-Frizzled) demonstrates pharmacodynamic (PD) modulation of the Wnt pathway in patients with advanced solid tumors[J]. Molecular Cancer Therapeutics, 2013, 12(11_Supplement): B24-B24. |
| | Vantictumab Preparation Products And Raw materials |
|